Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Health CatalystHCAT -1.17%50 Cash-to-Debt is 0.61 as of Jun. 2026, which is 55% below its 10-year median of 1.36. GuruFocus rates HCAT with a GF Score™ of 50/100 and a GF Value™ of $4.05 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Health Catalyst ranks worse than 55.07% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Health Catalyst's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.61.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Health Catalystcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Health Catalyst's Cash-to-Debt or its related term are showing as below:
HCAT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.53 Med: 1.36 Max: 4.54
Current: 0.61
During the past 9 years, Health Catalyst's highest Cash to Debt Ratio was 4.54. The lowest was 0.53. And the median was 1.36.
HCAT's Cash-to-Debt is ranked worse than 55.07% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.785
vs HCAT: 0.61
Health Catalyst (NAS:HCAT) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Health Catalyst Cash-to-Debt Related Terms
Health Catalyst Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Health Catalyst's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, Health Catalyst's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Health Catalyst Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Health Catalyst's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Health Catalyst's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Health Catalyst (HCAT) has a Cash-to-Debt of 0.61 as of Jun. 2026. This is 55% below median its historical median of 1.36. Over the past decade, Health Catalyst's Cash-to-Debt has ranged from 0.53 to 4.54. According to the industry distribution chart, Health Catalyst ranks #369 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 55.1%.
Is Health Catalyst's Cash-to-Debt too high?
Health Catalyst's current Cash-to-Debt of 0.61 is 55% below median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 4.54. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. Health Catalyst's value of 0.61 is 22.3% below this industry median. Based on the distribution chart, Health Catalyst ranks #369 out of 670 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Health Catalyst has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Health Catalyst's Cash-to-Debt compare to DH and CCLD?
According to the Healthcare Providers & Services industry distribution chart, Health Catalyst ranks #369 out of 670 companies for Cash-to-Debt. This places Health Catalyst in the lower half of its industry. The industry median Cash-to-Debt is 0.79. Health Catalyst's value of 0.61 is 22.3% below this benchmark. Historically, Health Catalyst's own Cash-to-Debt has ranged from 0.53 to 4.54 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 0.79, Health Catalyst has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Health Catalyst's current Cash-to-Debt of 0.61 is 22.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Health Catalyst's current Cash-to-Debt is 0.61, which is 55% below median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Catalyst stock overvalued right now?
Based on GuruFocus' analysis, Health Catalyst (HCAT) is currently considered Possible Value Trap. The stock's GF Value™ is $4.05, compared to a current price of $1.71 — trading 57.9% below its estimated fair value. The current Cash-to-Debt is 0.61, which is 55% below median its 10-year median of 1.36 and 22.3% below the Healthcare Providers & Services industry median of 0.79. Health Catalyst's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Health Catalyst (HCAT), the current Cash-to-Debt is 0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Health Catalyst (HCAT) Overvalued in 2026?
Based on GuruFocus' analysis, Health Catalyst stock appears to be undervalued.
The current stock price of $1.71 is trading 57.9% below its estimated GF Value™ of $4.05.
GuruFocus considers Health Catalyst to be Possible Value Trap.
Key valuation signals for HCAT:
Cash-to-Debt: 0.61 (55% below median its 10-year median of 1.36)
GF Value™: $4.05 vs. price of $1.71 (57.9% below fair value)
Industry Position: 22.3% below the Healthcare Providers & Services median (#369 of 670)
No single metric tells the full story. See the HCAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
50GF Score
Get the complete analysis for HCAT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCAT has been successfully added to your 
